Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 4/20 | 0.69 |
| ▸ | PDPK1 | O15530 | 7/20 | 0.67 |
| ▸ | AXL | P30530 | 2/20 | 0.62 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.60 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.55 |
| ▸ | GSK3B | P49841 | 2/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | AURKA | O14965 | 3/20 | 0.54 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.54 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.51 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.51 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.51 |
| ▸ | KDR | P35968 | 2/20 | 0.51 |
| ▸ | JAK3 | P52333 | 2/20 | 0.51 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.51 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.51 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.51 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30588952 | 0.88 | JAK2 (0.69) | JAK2AXLCHEK1FGFR1GSK3B | |
| SCHEMBL10213963 | 0.88 | JAK2 (0.69) | JAK2AXLCHEK1FGFR1GSK3B | |
| SCHEMBL12907241 | 0.82 | JAK2 (1.00) | JAK2PDPK1CHEK1GSK3BAURKA | |
| SCHEMBL3361070 | 0.82 | JAK2 (1.00) | JAK2PDPK1CHEK1GSK3BAURKA | |
| SCHEMBL6485242 | 0.80 | PDPK1 (1.00) | JAK2PDPK1CHEK1GSK3BAURKA | |
| SCHEMBL12907253 | 0.79 | PDPK1 (1.00) | JAK2PDPK1FGFR1AURKAAURKB | |
| SCHEMBL6480460 | 0.78 | PDPK1 (0.65) | JAK2PDPK1GSK3BAURKAAURKB | |
| SCHEMBL6490350 | 0.77 | GSK3B (0.60) | JAK2PDPK1AXLFGFR1GSK3B | |
| SCHEMBL6371302 | 0.77 | AXL (1.00) | PDPK1AXLFGFR1AURKAMEN1 | |
| SCHEMBL28871221 | 0.77 | KDR (0.67) | JAK2AXLFGFR1GSK3BAURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101962365-A | Aminoindazole derivatives as protein-kinase inhibitors | AVENTIS PHARMA SA | 2011-02-02 | — | — | CN | claimed |
| US-6949579-B2 | Aminoindazole derivatives and intermediates, preparation thereof, and pharmaceutical compositions thereof | AVENTIS PHARMA S.A. (FR) | 2005-09-27 | — | — | US | claimed |
| CN-1656078-A | Aminoindazole derivatives as protein kinase inhibitors | AVENTIS PHARMA SA (FR) | 2005-08-17 | — | — | CN | claimed |
| US-20040014802-A1 | Aminoindazole derivatives and intermediates, preparation thereof, and pharmaceutical compositions thereof | AVENTIS PHARMA S.A. (FR) | 2004-01-22 | — | — | US | claimed |
| EP-1487804-B1 | AMINOINDAZOLE DERIVATIVES AS PROTEIN-KINASE INHIBITORS | AVENTIS PHARMA SA (FR) | 2014-02-26 | — | — | EP | disclosed |
| US-20120053345-A1 | Indazole Compounds | ABBOTT LABORATORIES (US) | 2012-03-01 | — | — | US | disclosed |
| US-20120053345-A1 | Indazole Compounds | ABBOTT LABORATORIES (US) | 2012-03-01 | — | — | US | disclosed |
| US-8008481-B2 | Indazole compounds | ABBVIE INC. | 2011-08-30 | — | — | US | disclosed |
| US-8008481-B2 | Indazole compounds | ABBVIE INC. | 2011-08-30 | — | — | US | disclosed |
| CN-101962365-A | Aminoindazole derivatives as protein-kinase inhibitors | AVENTIS PHARMA SA | 2011-02-02 | — | — | CN | disclosed |
| US-20070282101-A1 | Indazole compounds | ABBVIE INC. | 2007-12-06 | — | — | US | disclosed |
| US-20070282101-A1 | Indazole compounds | ABBVIE INC. | 2007-12-06 | — | — | US | disclosed |
| WO-2007117465-A2 | INDAZOLE COMPOUNDS | ABBOTT LABORATORIES (US) | 2007-10-18 | — | — | WO | disclosed |
| US-6949579-B2 | Aminoindazole derivatives and intermediates, preparation thereof, and pharmaceutical compositions thereof | AVENTIS PHARMA S.A. (FR) | 2005-09-27 | — | — | US | disclosed |
| CN-1656078-A | Aminoindazole derivatives as protein kinase inhibitors | AVENTIS PHARMA SA (FR) | 2005-08-17 | — | — | CN | disclosed |
| US-20040014802-A1 | Aminoindazole derivatives and intermediates, preparation thereof, and pharmaceutical compositions thereof | AVENTIS PHARMA S.A. (FR) | 2004-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014802-A1 | Aminoindazole derivatives and intermediates, preparation thereof, and pharmaceutical compositions thereof | CYP2C8, NR0B2, NR2C2 | JAK2 1774/4885PDPK1 4495/4885AXL 329/4885 |
| US-20070282101-A1 | Indazole compounds | CYP3A43, CYP3A7, UGT1A1 | JAK2 1822/4885PDPK1 856/4885AXL 2872/4885 |
| US-20120053345-A1 | Indazole Compounds | CYP3A43, CYP3A7, UGT1A1 | JAK2 1822/4885PDPK1 856/4885AXL 2872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.